A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)

Trial Profile

A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Lucatumumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 18 Oct 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
    • 18 Oct 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
    • 10 Nov 2009 Actual initiation date (1 Sep 2005) and additional trial location (Australia) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top